Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 11(9): e0162199, 2016.
Article in English | MEDLINE | ID: mdl-27611077

ABSTRACT

BACKGROUND: The nucleotide analogue brincidofovir was developed to prevent and treat infections caused by double-stranded DNA viruses. Based on in vitro data suggesting an antiviral effect against Ebola virus, brincidofovir was included in the World Health Organisation list of agents that should be prioritised for clinical evaluation in patients with Ebola virus disease (EVD) during the West African epidemic. METHODS AND FINDINGS: In this single-arm phase 2 trial conducted in Liberia, patients with laboratory-confirmed EVD (two months of age or older, enrolment bodyweight ≥50 kg) received oral brincidofovir 200 mg as a loading dose on day 0, followed by 100 mg brincidofovir on days 3, 7, 10, and 14. Bodyweight-adjusted dosing was used for patients weighing <50 kg at enrolment. The primary outcome was survival at Day 14 after the first dose of brincidofovir. Four patients were enrolled between 01 January 2015 and 31 January 2015. The trial was stopped following the decision by the manufacturer to terminate their program of development of brincidofovir for EVD. No Serious Adverse Reactions or Suspected Unexpected Serious Adverse Reactions were identified. All enrolled subjects died of an illness consistent with EVD. CONCLUSIONS: Due to the small sample size it was not possible to determine the efficacy of brincidofovir for the treatment of EVD. The premature termination of the trial highlights the need to establish better practices for preclinical in-vitro and animal screening of therapeutics for potentially emerging epidemic infectious diseases prior to their use in patients. TRIAL REGISTRATION: Pan African Clinical Trials Registry PACTR201411000939962.


Subject(s)
Antiviral Agents/therapeutic use , Cytosine/analogs & derivatives , Ebolavirus/physiology , Hemorrhagic Fever, Ebola/drug therapy , Organophosphonates/therapeutic use , Adult , Antiviral Agents/pharmacology , Cytosine/pharmacology , Cytosine/therapeutic use , Ebolavirus/drug effects , Female , Hemorrhagic Fever, Ebola/virology , Humans , Liberia , Male , Middle Aged , Organophosphonates/pharmacology , Treatment Outcome , Young Adult
2.
PLoS Med ; 13(4): e1001997, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27093560

ABSTRACT

BACKGROUND: TKM-130803, a small interfering RNA lipid nanoparticle product, has been developed for the treatment of Ebola virus disease (EVD), but its efficacy and safety in humans has not been evaluated. METHODS AND FINDINGS: In this single-arm phase 2 trial, adults with laboratory-confirmed EVD received 0.3 mg/kg of TKM-130803 by intravenous infusion once daily for up to 7 d. On days when trial enrolment capacity was reached, patients were enrolled into a concurrent observational cohort. The primary outcome was survival to day 14 after admission, excluding patients who died within 48 h of admission. After 14 adults with EVD had received TKM-130803, the pre-specified futility boundary was reached, indicating a probability of survival to day 14 of ≤0.55, and enrolment was stopped. Pre-treatment geometric mean Ebola virus load in the 14 TKM-130803 recipients was 2.24 × 109 RNA copies/ml plasma (95% CI 7.52 × 108, 6.66 × 109). Two of the TKM-130803 recipients died within 48 h of admission and were therefore excluded from the primary outcome analysis. Of the remaining 12 TKM-130803 recipients, nine died and three survived. The probability that a TKM-130803 recipient who survived for 48 h will subsequently survive to day 14 was estimated to be 0.27 (95% CI 0.06, 0.58). TKM-130803 infusions were well tolerated, with 56 doses administered and only one possible infusion-related reaction observed. Three patients were enrolled in the observational cohort, of whom two died. CONCLUSIONS: Administration of TKM-130803 at a dose of 0.3 mg/kg/d by intravenous infusion to adult patients with severe EVD was not shown to improve survival when compared to historic controls. TRIAL REGISTRATION: Pan African Clinical Trials Registry PACTR201501000997429.


Subject(s)
Antiviral Agents/therapeutic use , Ebolavirus/genetics , Hemorrhagic Fever, Ebola/drug therapy , RNA, Small Interfering/therapeutic use , RNA, Viral/genetics , RNAi Therapeutics/methods , Adult , Aged , Aged, 80 and over , Ebolavirus/pathogenicity , Female , Hemorrhagic Fever, Ebola/diagnosis , Hemorrhagic Fever, Ebola/genetics , Hemorrhagic Fever, Ebola/mortality , Hemorrhagic Fever, Ebola/virology , Host-Pathogen Interactions , Humans , Infusions, Intravenous , Male , Middle Aged , Nanoparticles , RNA, Small Interfering/administration & dosage , RNA, Viral/blood , RNAi Therapeutics/adverse effects , Sierra Leone , Survival Analysis , Time Factors , Treatment Outcome , Viral Load/drug effects , Viral Load/genetics , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...